Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 1/20 | 0.51 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.51 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.51 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | FPR3 | P25089 | 1/20 | 0.38 |
| ▸ | FPR2 | P25090 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | NAAA | Q02083 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22123103 | 0.92 | GNAI3 (0.47) | GNAI3GNAO1GNAI1CA14SMN1; SMN2 | |
| SCHEMBL3387935 | 0.88 | NAAA (0.44) | GNAI3GNAO1GNAI1CA14SMN1; SMN2 | |
| SCHEMBL28605405 | 0.80 | GNAI3 (0.57) | GNAI3GNAO1GNAI1SMN1; SMN2FPR3 | |
| SCHEMBL20142152 | 0.80 | GNAI3 (0.63) | GNAI3GNAO1GNAI1SMN1; SMN2ALDH1A1 | |
| SCHEMBL27123113 | 0.79 | ITGB3 (0.37) | GNAI3GNAO1GNAI1 | |
| SCHEMBL13419014 | 0.77 | GNAI3 (0.52) | GNAI3GNAO1GNAI1SMN1; SMN2FPR3 | |
| SCHEMBL6657369 | 0.76 | ITGB3 (0.39) | GNAI3GNAO1GNAI1 | |
| SCHEMBL26098963 | 0.75 | DDB1 (0.32) | FPR3FPR2 | |
| SCHEMBL31040440 | 0.75 | CA14 (0.50) | CA14FPR3FPR2TDP1MEN1 | |
| SCHEMBL13622518 | 0.75 | TDP1 (0.60) | CA14TDP1MEN1KMT2AEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3898630-B1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2023-05-10 | — | — | EP | disclosed |
| US-20230022724-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-26 | — | — | US | disclosed |
| US-20230013602-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-19 | — | — | US | disclosed |
| US-20230017532-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-19 | — | — | US | disclosed |
| EP-3898631-B1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIALS | HOFFMANN LA ROCHE (CH) | 2023-01-18 | — | — | EP | disclosed |
| EP-3898629-B1 | IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIALS | HOFFMANN LA ROCHE (CH) | 2023-01-18 | — | — | EP | disclosed |
| US-20230012368-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-12 | — | — | US | disclosed |
| US-20230011869-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-12 | — | — | US | disclosed |
| EP-3897839-A1 | IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIAL AGENTS | F. Hoffmann-La Roche AG (CH) | 2021-10-27 | — | — | EP | disclosed |
| EP-3898629-A1 | IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIALS | F. Hoffmann-La Roche AG (CH) | 2021-10-27 | — | — | EP | disclosed |
| CN-113226469-A | Imidazopyrazine derivatives as antibacterial agents | 豪夫迈·罗氏有限公司 | 2021-08-06 | — | — | CN | disclosed |
| CN-113195496-A | Imidazopyrazine derivatives as antibacterial agents | 豪夫迈·罗氏有限公司 | 2021-07-30 | — | — | CN | disclosed |
| CN-113195498-A | Novel imidazopyrazine derivatives | 豪夫迈·罗氏有限公司 | 2021-07-30 | — | — | CN | disclosed |
| CN-113195497-A | Novel imidazopyrazine derivatives | 豪夫迈·罗氏有限公司 | 2021-07-30 | — | — | CN | disclosed |
| CN-113164771-A | Imidazopyrazine derivatives as antibacterial agents | 豪夫迈·罗氏有限公司 | 2021-07-23 | — | — | CN | disclosed |
| WO-2020126954-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2020-06-25 | — | — | WO | disclosed |
| WO-2020127075-A1 | IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIALS | F. HOFFMANN-LA ROCHE AG (CH) | 2020-06-25 | — | — | WO | disclosed |
| WO-2020126956-A1 | IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2020-06-25 | — | — | WO | disclosed |
| WO-2020126953-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIALS | F. HOFFMANN-LA ROCHE AG (CH) | 2020-06-25 | — | — | WO | disclosed |
| WO-2020126952-A1 | IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2020-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230022724-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | MRPL21, O60361, MYD88 | GNAI3 874/4885GNAO1 1535/4885GNAI1 169/4885 |
| US-20230011869-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | MRPL21, O60361, MYD88 | GNAI3 874/4885GNAO1 1535/4885GNAI1 169/4885 |
| US-20230017532-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | MRPL21, O60361, MYD88 | GNAI3 826/4885GNAO1 1432/4885GNAI1 153/4885 |
| US-20230013602-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | IL4, RPS4Y1, RPS4X | GNAI3 798/4885GNAO1 2376/4885GNAI1 545/4885 |
| US-20230012368-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | MRPL21, MYD88, IL1R1 | GNAI3 753/4885GNAO1 1613/4885GNAI1 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.